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Abstract
Background: Despite significant advancements in new treatment modalities for rheumatoid arthritis with biological
therapies, foot complications remain a disabling and common feature of the disease. In this study the aim was to
explore and describe the personal experiences of people with rheumatoid arthritis in receipt of biologic treatments
in a bid to understand the impact of this form of medication on their mobility.
Methods: An interpretative phenomenological analysis (IPA) was undertaken to explore in depth the individual
experience of rheumatoid disease through personal accounts of the patient journey spanning both ‘before’ and
‘after’ the instigation of biologic therapy. A purposive sampling strategy was adopted and in-depth semi structured
interviews used to facilitate rich, detailed interview data exploring the lived experiences of individuals undertaking
biological therapy and the changes to mobility experienced as a result. Thematic analysis was employed with an
IPA framework to identify key meanings, and report patterns within the data.
Results: Five people with rheumatoid arthritis participated in the study. The mean disease duration was 20.2 years
(range: 6 -32) and all were being treated with biologic therapies. Four key themes emerged from the data: 1) Life
before biologic treatment, depicted in accounts as a negative experience characterised by painful and disabling
symptoms and feelings of hopelessness. 2) Life with biologic treatment, often experienced as a life changing
transition, restoring function and mobility and offering renewed hope. 3) Sense of self, in which the impact of
rheumatoid disease and the subsequent changes arising from biologic therapy reveal a profound impact on
feelings of personal identity both pre and post biologic therapy; an effect of footwear on self-image emerges as a
dominant sub theme; 4) Unmet footcare needs were evident in the patient narrative, where the unrelenting if
diminished impact of foot pain on mobility was viewed in the context of problematic access to foot health services.
Conclusion: Whilst the findings from this study mirror those within the existing literature, which report
improvements in physical function related to biological therapy, foot problems clearly remained an unremitting
feature of life for patients with rheumatoid disease, even when in receipt of biologics.
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Background
Rheumatoid arthritis (RA) is the most common form of
chronic inflammatory polyarthritis [1] with a relatively
constant prevalence across many developed populations
worldwide, including the UK at 0.5-1.0% [2]. Improved
understanding of the molecular pathways responsible for
driving the disease are demonstrated in the variety of bio-
logic treatments now available, each with varying im-
munological targets and modes of action [3]. There is a
growing body of evidence demonstrating improvements in
patient outcome measures in those taking biologics [4–7],
although much of this evidence is derived from quantita-
tive research studies, with relatively little attention focused
on the individual patient experience.
The prevalence of foot involvement and foot pain in
RA is well documented in the literature with an esti-
mated range of 35-70% [8, 9]. Despite the significant
advances in new treatment modalities for RA, such as
the availability of disease modifying anti-rheumatic drugs
(DMARDs) and biologic treatments, foot complications
remain a disabling and common feature of life for many
patients [9]. Indeed, the presence of forefoot pain
(63.9%) and ankle pain (42.7%) was highlighted by Otter
et al. [9] from a cross sectional survey of patients with
RA (N = 585). However, these estimates may actually be
higher, as the prevalence of foot involvement and the
extent of foot symptoms in the RA patient group can be
under-estimated [9, 10].
Foot complaints and impaired foot function occurring
in both the early and chronic stages of RA have been
shown to severely limit an individual’s daily activities, in
particular reducing ambulation and functional mobility
[11–14]. Pain from rheumatoid forefoot disease has also
been linked to disability in a number of weight bearing
activities [14]. Indeed, in a survey by Grondal et al. [12]
forefoot symptoms were reported as a primary cause in
walking impairment in the rheumatoid population, signifi-
cantly more so than symptoms from either the knee or
hip joints (N = 1000). Consequently, investigators have
begun to highlight the negative impact of RA related foot
disease on quality of life (QOL) [15, 16] although few
studies have demonstrated this unequivocally [17].
A new paradigm for the management of foot mani-
festations of RA has been proposed, which includes
tighter disease control through the use of biologic
treatments [18]. Other investigators have shown that
patient reported foot pain and disability may decrease
in people who have RA (PwRA) following 12 weeks of
anti-TNFα treatments compared to those on conventional
DMARDs [19]. Conversely, in a study comparing self-
reported foot pain in PwRA treated with and without
anti-TNFα, Otter et al. [9] found that foot pain was
significantly increased within the anti-TNFα treated group
(P = 0.012). The authors suggest that the success of the
TNF inhibitors may encourage a greater degree of mobil-
ity in the patients receiving it, which in turn may increase
foot symptoms [7, 9, 20]. This may be evidenced by ob-
served improvements in gait amongst PwRA successfully
treated with anti-TNFα [21].
From an extensive review of the literature it is clear
that very little evidence is available to confirm these
theories. Three key qualitative publications have been
identified within the area of biologics and experiences of
PwRA. Marshall et al. [22] reported improvements in
physical function, pain and well-being using interview
data (N = 19). They indicated a greater range of benefits
from biologic treatments than those routinely measured
in quantitative research [22]. Arkell et al. [23] found that
participants were very positive about anti-TNFα medica-
tion, which they felt led to dramatic changes in their
physical symptoms. Equally, Linden and Bjorklund [20]
concluded that successful treatment with anti-TNFα
medication led most participants to experience dramatic
improvements in the quality of their lives, resulting in a
return to leisure interests, enhanced social activity and
improved or continued productivity in education and/or
occupation. However Linden and Bjorklund also cau-
tioned that such dramatic changes may risk overuse and
consequent strain [20].
A constant challenge for service providers remains the
appropriate targeting of resources, which ideally would
be guided by patient reported experiences, particularly
where pharmacological management is especially effect-
ive at reducing pain and disability. This is very notable
in relation to patient experiences of mobility in those
who have commenced anti -TNFα drug therapy. As a
result, the aim of this study was to gain a deeper under-
standing of the experiences of PwRA who are receiving
biological therapy treatment in relation to their lower
limb mobility.
Methods
A qualitative research study design was employed to
enable a deep exploration of the lived experiences of
individuals with RA in receipt of pharmacological
treatment with biologic therapies, which would exam-
ine the impact of these treatments on their world.
Interpretative phenomenological analysis (IPA) pro-
vided the most appropriate approach. IPA is a qualita-
tive approach that involve an idiographic focus which
is concerned with providing insights into how a individual
in a specific context make sense of a particular issue
(phenomenon) [24]. In this study, this involved trying to
understand the unique personal meanings and actual
experiences of PwRA patients attempting to regain and
maintain mobility whilst receiving biological therapy treat-
ment. This exploratory idiographic approach was adopted
using semi structured interviews, and it deployed a
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chronological narrative mapping of experiences before the
onset of RA, after its onset, and the journey through the
transition to biologic therapies and their impact, thus
spanning a significant timeframe in the participants’ lives.
Ethical approval
Full ethical approval for the study was granted by the
Faculty of Health Sciences, University of Southampton
Ethics Committee via the online approval system ERGO
(Ethics and Research Governance Online). Our original
proposal had a tighter inclusion criteria for specific anti-
TNF therapies, however this substantially reduced our
potential recruitment sample and therefore we widened
our criteria to include PwRA who were receiving any
biologic therapy. The amendment to extend the sample
to include patients receiving all current biologics rather
than just one specific branch, anti-TNFα was approved.
Participants
Participants were recruited through branch membership
of the National Rheumatoid Arthritis Society (NRAS)
using the Salisbury and North Hampshire branches. All
members of NRAS have rheumatoid arthritis. Potential
participants were approached with a short presentation
that explained the study by the primary investigator (LS)
at the meeting of each branch. Those interested in join-
ing the study were provided with an information sheet
along with the contact details of the primary investigator
(LS). Individuals volunteering to join the study then
contacted the primary investigator (LS) for additional
information, to have any further questions answered,
and to be pre-screened against the inclusion criteria.
A purposive sampling strategy was undertaken, con-
sistent with the qualitative paradigm and study design
adopted. This enabled the study to capture insightful
and meaningful data exploring individual patient ex-
periences, and to note any common experiences
across the sample. Participants were included if they
had a confirmed diagnosis of rheumatoid arthritis;
were currently receiving biologic treatment, where the
duration of biologic treatment was over 6 months;
where they were aged 18 or over and were able to
give consent to participate in the study. Participants were
excluded if they had a diagnosis of inflammatory arthritis
other than rheumatoid arthritis, or were unable to speak
or understand English.
Procedure
Individual, face-to- face, semi-structured interviews
were undertaken, generating data which was tran-
scribed verbatim prior to analysis. Each interview
was conducted by one researcher (LS) to enable
consistency in approach, whilst also capturing indi-
vidual accounts and narratives. An interview topic
guide (Additional file 1) was used to enable a degree
of continuity across the interviews, whilst acknow-
ledging the need to capture the individual experi-
ences of each participant. To begin the interview a
broad open question about the participant’s experi-
ences of everyday life with rheumatoid arthritis prior
to biologic therapy was used. The answers were then
followed up with exploratory questions, probes and
prompts. As there has been little published work on
patient experiences of RA when undergoing biologic
therapy, the topic guide was informed by, and con-
structed from, the clinical experience of the research
team. Participants were able to choose the venue of
the interviews, either in their own homes or in a
room at the University of Southampton. The inter-
views lasted between 40-60 min each and all were
audio-recorded. Interview audio recordings were
transcribed verbatim. One researcher (LS) read and
re-read transcripts several times to enable familiarity
and immersion of the data. To verify the accuracy of
the researcher’s transcription, the first participant
was offered a copy of their transcribed interview to
check for veracity, accuracy and to ensure rigour
which was confirmed by the individual participant
(respondent validation).
Thematic analysis was used to analyse the data within
an IPA framework focussing on the individual lived ex-
perience. One researcher (LS) undertook a line by line
analysis of the experiences and understanding of each
participant. These initial notes were used to develop
codes which informed the further development of
themes and sub-themes. Codes were generated from
transcripts by noting recurring words or comments of
interest. Following this process all codes were then laid
out and collated into groups of similar features which
served as potential themes. The emerging themes were
discussed and viewed by the wider research team (LS,
MDH, CB) to verify the themes, identity any additional
areas of interest and agree the themes. This involved
discussion and looking at patterns across the data, but
did not involve each member analysing the data individ-
ual and then comparing the finding. To further develop
the themes and make clear links to the transcripts,
extracts from the transcripts were collated into a table
for ongoing analysis (Additional file 2). Potential themes
were then discussed again with the research team (LS,
MDH, CB) to identify any alternative interpretations.
The process of verifying themes as a team provided a
more rigorous approach, different perspective and
agree on the final themes.
Results
The study recruited seven participants, two male and
five female from the two NRAS branches. However
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one female participant was unable to attend interview
and therefore withdrew. One further interview was
initially postponed and the participant opted to with-
draw. Five interviews were finally conducted that in-
cluded one male and four female participants (mean
age 64, range 35 to 78 years). The average duration
of disease was 20.2 years (range 6–32 years). The
average duration of receiving biologic therapy was
5.4 years (range 2005–2013), although several partici-
pants had been on other biologics before and these
were brought up in the interviews. At the time of the
interviews, the participants were experiencing varying
degrees of effectiveness of their biologic treatments.
Two participants were having infusions of Rituximab,
one of which was waiting to change to Abatacept due
to poor efficacy. Two participants were having
Humira injections and one patient was having Enbrel
injections. Three participants had no prior history of
biologic drug therapy, whilst one participant was
awaiting the start of a third different biologic and an-
other was starting on a fourth.
The analysis identified four key themes: 1) Life before
biologic treatment, 2) life with biologic treatment, 3)
sense of self, and 4) podiatric implications. Each theme
is discussed and supported with direct extracts drawn
from the transcripts. Participants are assigned numerical
identifiers to ensure confidentiality.
Life before biologic therapy: “If you did too much you
went to bed”
This theme related to individuals experiences and key
events in the years prior to the receipt of biologic ther-
apy, including the physical, social and emotional impact.
Some of these accounts convey the experience of a dark
period in participants’ lives, associated with “survival”
and a time “not to visit again”.
Each account captured the contrast between life
prior to biologic therapy and that after it, providing a
context within which to comprehend the extent of
the impact of the drugs. Symptoms of pain were
common to all the participants, albeit to a varying de-
gree. However, the intensity of the impact of living
with pain is captured in the concise but descriptive
and powerful phrases employed by some of the fe-
male participants, all of whom were diagnosed more
than 10 years previously.
“Every single joint is on fire” (P01)
“Absolute agony; if you just touched me I would
scream with the pain” (P02)
“A normal day was agony” (P03)
“The damage comes with really severe pain” (P05)
All participants clearly experienced the undesirable
and troublesome impact of physical symptoms arising
from rheumatoid arthritis, with each identifying a
range of distressing and disabling restrictions, includ-
ing ‘tiredness’ and ‘exhaustion’. One short data extract
particularly captures the extent of the disabling im-
pact of their symptoms.
“[I] usually went back to bed after breakfast because I
needed to” (P03)
Joint and limb stiffness as much as pain were viewed
as disabling, preventing the accomplishment of the
simplest of everyday tasks.
“When I got up in the mornings it took me about 20 min
to be able to walk normally…my arms stopped working; I
actually couldn’t raise them over shoulder height” (P04)
Participants also described the experience of becoming
less active, or diminishing physical capabilities, leaving a
sense of loss and requiring a re-evaluation of self-image
and identity. For example, those participants who had
previously participated in sport had been forced to
abandon it altogether.
“I was playing tennis at the time, just got back into
tennis, so I stopped doing that, um, and I used to run,
just road running - I couldn’t do any of that. And then
just general things, getting out on the bikes or going
swimming, that all stopped.” (P04)
Strong emotional feelings were expressed when dis-
cussing life prior to being treated with biologic therapy.
One participant in particular (P05) found it very ‘emo-
tional and difficult’ talking about the time around her
diagnosis, becoming quite tearful on several occasions
and expressing suicidal thoughts.
“It had got so bad [pauses] I could understand how
somebody could top themselves…..you know, the pain
was just so bad” (P01)
“You just want to lay in bed and [pause] just be left
alone and [pause] die in your own way, if you know
what I mean, ‘cos the pain is so excruciating” (P02)
Loss of sense of self and self- identity were very
evident, where comparisons were drawn between the
person they had been (active, sporty) to that which
they had become (disabled).
“I’d gone from being very active to sitting on the stairs
crying” (P05)
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Life with biologic therapy: “I’m doing more than I
thought possible”
This theme relates to participant narratives reporting
experiences since commencing biologic therapy. All par-
ticipants reported the remarkably liberating effects of
what was described as a ‘miracle’ treatment, even refer-
ring to life as ‘glorious’ in some cases.
“It has just kind of given me back my life…..and that is
such a good thing.” (P01)
Each narrative was marked by the use of highly evoca-
tive and descriptive language suggestive of a dramatic
life-changing event, evident when the biologic treatment
was effective.
“When I had this Enbrel, it was just like being reborn
actually, quite life changing” (P02)
“God, it was incredible, absolutely incredible….it was
just the most amazing thing…I think that’s what is
amazing about it, is that you appreciate things more…
it’s like a gift” (P05)
The startling effectiveness of the biologic therapy also
enabled participants to re-engage with physical activities
that were presumed lost for ever, prompting them to
take every opportunity to do so.
“I can go and do things, so any chance now I get, I
go!” (P01)
“I can even push a lawn mower now!” (P02)
“I ran the great south run this year” (P04)
“I walk up the hill, it’s in a valley, and it’s a really
steep hill and I’ve been on health walks with the local
health group walk. And I walk on my own, and I walk
for an hour (P05)
Unsurprisingly, the ability to resume physical activities
that had seemed unlikely prior to biologic therapy
brought a sea change in mood and an uplift in psycho-
logical well-being.
“Well I think it, umm, I think it cheers you up a
lot. A lot of it is in the mind, and when you are
happy your pain is less anyway, and you can do
more….So mentally it makes your life much better”
(P02)
“I walked miles, and it was just incredible and I felt so
much better in myself” (P05)
Not all the respondents experienced such dramatic
improvements, particularly those who had tried several
biologics previously, but had experienced a reduced
tolerance of the drug or a failure in efficacy, or, in some
cases, a regression and resumption in symptoms, with
an understandable loss of optimism.
“What was so difficult was that 9 months later the
drug (Infliximab) almost overnight stopped working…It
was almost worse than having it, it was like re-visiting
where I was in the first place…Part of me always
thinks wouldn’t it be wonderful if I can find something
like Remicade (Infliximab) again, that was 100%, that
put me into remission that I know is possible” (P05)
“Enbrel must have helped with that (walking) but the
Rituximab hasn’t quite managed to keep it up. I’ve gone
back a bit, quite a bit really…Feet, my feet seem to have
got much worse….whether I can blame the Rituximab for
that I don’t know, but it certainly has got worse” (P03)
Equally, in some instances respondents had experienced
a remission in symptoms of pain and stiffness, and had
avoided irreversible joint damage and deformities, but
nevertheless had been left with some residual effects
and limitations to everyday activity, often met with
resignation.
““I think every joint has gone back to roughly being ok…I
think the biggest thing for me is the fatigue…There are
times when I can’t keep playing with them (children)
and I do have to come and sit down, which gets me a
bit frustrated. So, so [pause] yeh it has become the
‘norm’ so I don’t think about it as much and I have
just accepted that I have to come and do it” (P04)
Sense of self: “You’re a woman & want to feel nice”
Bury’s classic work (1982) on biographical disruption
powerfully captured the impact of the onset and deteri-
oration of rheumatoid disease on personal identity and
self-image, and Williams’s subsequent work on bio-
graphical reconstruction (1984) took account of the
normalisation process following successful medication,
although neither works were able to address the changes
heralded by the modern use of biologic therapy [25, 26].
Unsurprisingly, notions of self-identity and self-image
were, as evidenced in the data presented here, trans-
formed with the advent of biologic therapy, although
established signs of disease continued to result in feelings
of being labelled.
With deformity established as a residual effect of earlier
active disease, participants reported a self-consciousness
generated by the knowledge that visible signs of their
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disease, such as found in the hands, were highly noticeable
to others around them.
“I was standing in the supermarket queue and I saw
that someone else had the same hands as me and I
knew that she’d got rheumatoid too and it’s like I’m an
individual, I don’t wanna be part of this club, I don’t
want this label” (P05)
Individual sense of self-image may be drawn from, and
constructed around, a sense of how individuals are seen
by others, which was evident in the data and seemed to
reflect a desire to be viewed as ‘normal’ in one’s public
self (‘normalisation’ as a form of coping, bracketing off
the impact of the disease – see Williams [27]), which
also maps with William’s reflections [27] on ‘corporeal
dysappearance (dysfunctional appearance)’.
“I do try and walk without a stick around the town, so
that I’ve not always got a stick. And sometimes you think,
ooh, why didn’t I get the stick out the car? But the point is,
umm, that way [pause] I’m just normal! [laughs]” (P01)
Self-image, personal identity and the participants’
‘public self ’ was most evidently affected in accounts
concerning the individuals’ social life. For example, one
participant spoke about friends who had met partners
via online dating sites, contrasting this with her own
situation in which she felt unable to consider any
such activity as realistic or feasible, given her physical
appearance.
“It can be embarrassing, [pause] I mean, [pause] I’d
never do this online dating, cos I’d have someone have
to see me first [sic]. See what my hands are like. I
couldn’t have someone never see me and then see
things like disabled crippled hands” (P02)
Another element of concern expressed about the
effects of changed physical appearance was the focus
on the accompanying special footwear often pre-
scribed for patients with particular foot problems,
such as deformity. In such cases, it was no longer
possible to walk comfortably, or fit into, ‘ordinary’
footwear (that which might be purchased in a high
street shoe shop). However, prescription orthopaedic
footwear is notable for its bulky, functional appear-
ance, with very little aesthetic consideration in its
design, a matter of particular concern to female pa-
tients. Wearing such footwear therefore marks out
the individual, highlighting the disability.
“How can you wear things like that, even no matter
how much pain I was in there was no way I’m gonna
be seen dead in them, I’m not even gonna be put in
my coffin in one of those on me” [sic] (P02)
“I have to wear these (pause) ghastly things (laughs) to
get any degree of comfort” (P03)
“Have you ever seen those great big shoes? I said I
can’t wear that, that is insulting really. I still wanna
be, I’m still a woman!” (P02)
Theme 4. Podiatric Implications: “They never tell you
anything about your feet”
In some instances the reported beneficial effects of
biologic therapy did not extend to foot pain. Whilst
global pain had diminished, foot pain remained. This
may have been due to established deformity acquired prior
to biologic therapy, or a consequence of foot surgery.
“The pain has improved all over with the Enbrel
injections, yeh,that I can’t deny. But my pain in my
feet, my feet are still bad because as I say I’ve had all
the operations, and the deformity.” (P02)
Access to allied healthcare professionals was an area of
importance to all participants; all the participants re-
ported finding it difficult to access services, due to a lack
of referral, with the common consensus being that
“you’ve got to go and ask for it” (P01). In addition, it is
clear that a lack of inter-professional co-ordination ham-
pers effective and timely referral, and the criteria
adopted for referral may appear iniquitous.
“Umm to be honest I don’t know if it’s something they do
with everyone [refer to PT & OT] or just, they did say my
RA was quite severe and had come on suddenly. I don’t
know if that’s why they did it or because I was asking
them for help. I think at the time I was asking for things
that I could do to try and keep myself more mobile.”(P04)
Access to podiatry services specifically appears par-
ticularly problematic, possibly due to a lack of awareness
by other professionals of the roles within podiatry.
“…I have never seen a podiatrist … I’ve never been
recommended to see one…” (P01)
“They [nurses and physicians] feel your knees and sorts
of things and see how you can move your ankles but
they never seem to bother much about the feet” (P02)
“I’m sure I mentioned it to my GP and rheumatologist
umm but I think that was just part of the overall
symptoms and my feet individually weren’t really
looked at” (P04)
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Discussion
Exploring the lived experience of individuals with
rheumatoid arthritis in receipt of biologic therapy marks
a step forward from the work of Bury [25] and Williams
[26], in that it allows a glimpse into the world of patients
whose lives have been transformed by these new drugs.
Whereas Bury and Williams established and developed
the concepts of biographical disruption and biographical
reconstruction, the advent of biologics treatment has
opened the door to a new dimension in the subsequent
normalisation process. In this paper the focus has been
on those elements of individual life experience which
impact on mobility and self-image, capturing both the
life before and the life after biologic therapy. In doing so
it allows the links between transformative drug therapy
use and personal self-identity to be explored, and to
examine ways in which this modifies or reflects the pro-
cesses outlined by Bury and Williams in their seminal
works [25, 26]. The participant narratives in this study
resonate strongly with those identified by Bury, Williams
and others in examining the impact of chronic illness
and the disabling effect on mobility and physical changes
that effect self-image. Following biologic therapy, the
narratives assume a quite different course – an accelerated
form of normalisation which brings its own unique prob-
lems; notably overuse of joints, ligaments and soft tissues
in previously damaged, deformed and vulnerable feet.
Broadly, the experiences of biologic therapy reported
by the participants suggested a dramatic and significant
improvement in symptoms, enabling a return to near
normal activity in some instances. These findings are
largely consistent with Marshall et al. and Arkell et al.
[22, 23], although they explored the effects of anti-
TNFα only, rather than the wider group of biologic
drugs. Unsurprisingly, the changes noted in those start-
ing biologics were linked to perceived improvements in
quality of life (QOL). Similar results were also found in
a range of recent quantitative studies, with anti- TNFα
treatment shown to significantly improve health related
QOL [4, 28].
Another important finding from our study was the
dramatic improvement in the degree of physical activity
and participation possible as a result of biologic therapy.
This is consistent with the conclusions reached by other
investigators [4, 9, 20, 28].
It is clear that the value of the physical improvements
resulting from biologic therapy was transformative,
bringing with them a feeling of well-being through re-
engaging in physical activity. Linden and Bjorklund [20]
also reported improved physical and mental well-being
in patients treated with anti- TNFα, as did Loeppenthin
et al. [29], where patients were treated with biologics.
In the accounts presented here, it is clear that those
participants who experienced a return to near normal
physical activity following biologic therapy appeared to
normalise rapidly, to the extent that their expectations
of life were raised to that of life as it was before the ad-
vent of disease. To feel restored to normal function and
ability naturally encouraged the participants to attempt
to engage in activities in the way they may have done
prior to the onset of RA. For those patients with
advanced or chronic long standing disease, this may not
be a realistic expectation, given the extent of muscle atro-
phy and fatigue or deformity that may have accumulated
over a number of years prior to commencing biologics.
PwRA overstraining themselves due to receding symp-
toms and a resultant normalisation is highlighted by
Linden and Bjorklund [20]. Although patients may need
to learn to balance their ‘re-born’ lifestyle with enough
rest, our findings agree with those of Linden and Bjork-
lund [20] and suggest that further input from allied
health professionals may be beneficial in assuming a
more measured approach to regaining activity. For PwRA
who are positive responders to biologics, those with early
access and recent diagnosis may require different inter-
ventions to those with long-standing chronic disease, as
the latter may have a greater level of tissue damage,
deformity or history of surgery. Those PwRA with chronic
disease who ‘over-do-it’ may experience such complica-
tions as tissue viability loss due to increased activity
involving vulnerable structures, as described by some
participants.
In such circumstances podiatrists are able to monitor
areas at risk of ulceration occurring from increased de-
mand. Avoiding ulceration is critically important, given
the enhanced risk of infection associated with taking
biologic drugs, and the potential for flares if treatment is
temporarily stopped. Prescription foot orthoses may also
provide additional protection and help to minimise the
dangers of overuse of the feet.
A lack of choice surrounding footwear could impact
upon the negativity expressed regarding the aesthetics of
the orthopaedic footwear issued to some patients. This
is already acknowledged in the current literature by
Williams et al. who suggest that footwear may reinforce
a negative self-image [30]. Similar themes around iden-
tity and footwear were also found by Farndon et al, how-
ever they also highlighted conflict in what podiatrists
and the people that they support and treat look for in a
shoe [31]. Biologics might make a person feel better phys-
ically, but established deformity is irreversible and a dam-
aged self-image may therefore persist. Footwear aesthetics
may need to be acknowledged and addressed by clinicians
if patients are to effectively use prescription shoes.
Importantly, if we are to acknowledge that effective
response to biologics can lead to improved physical
function and increased physical activity, combined with
improved foot function, and that ‘over use’ may be an
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unintended consequence, then a role in closely monitoring
foot health in these patients is clear.
It is also clear that podiatrists may provide that service,
as is acknowledged in both the literature and in clinical
guidelines, which recommend access to a specialist in foot
health such as a podiatrist for assessment and review of
foot health needs [16, 32, 33]. Despite this, there appears
to be a lack of access to podiatry services for PwRA and
this has been consistently reported within the recent
literature relative to the UK [34, 35] and other coun-
tries [13, 36]. Whilst new models of foot care for
PwRA have been proposed [37, 38] further explor-
ation of these is recommended for implementation of
such strategies within routine practice.
Study limitations
A reflection on the study methodology is relevant, given
the sample size was less than expected. By incorporating
the experiences of a wider group of people more themes
may have been generated, or the current themes identified
may have been seen as more or less significant. It is likely
that age at diagnosis, disease duration and experiences of
illness before accessing biologics are key variables.
Although this varied in participants for this study, a larger
sample would have enabled comparisons between vari-
ables such as differing lengths of disease duration. Finally,
recruitment from a support group for PwRA could
mean that the participants were well motivated and
may have influenced the data obtained. If we had
sought participants outside of this group we may have
resulted in a different narrative.
Conclusion
The findings from this study advance the work of Bury
and Williams, and highlight the personal and social
impact of biologic therapy on patient mobility. Most
participants experienced dramatic changes in their daily
lives due to a reduction in symptoms from effective bio-
logic treatment. However, it is clear that there are conse-
quences to this improvement in function, in that over
exertion may lead to further foot problems, highlighting
a need for specialist foot health care monitoring and
improvements in patient education which could be
provided by podiatrists.
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